Physicians’ Education Resource
Last Modified: May 20, 2010
Conference Dates: August 20-22, 2010
Conference Location: United States
Sponsoring Group: Physicians’ Education Resource
Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/529
Topics Covered: At the conclusion of this congress, you should be able to: Discuss approaches to target the tumor microenvironment for cancer therapy Describe approaches to inhibit DNA repair and disrupt the cell cycle in cancer cells Evaluate data on inhibitors of novel signaling pathways in cancer therapy Assess the role of new imaging techniques in drug delivery and monitoring response Evaluate strategies to induce apoptotic signaling in tumor cells Appraise new approaches to develop immunotherapeutic agents in cancer therapy Discuss approaches to target protein homeostasis for cancer therapy Identify appropriate clinical trials of novel targeted agents that benefit specific groups of patients with cancer.
Conference Objectives: Designed to provide participants with cutting-edge information on novel targeted anticancer therapies now in development, including the most current clinical data on those agents as well as information on their mechanisms of action. The congress will provide a unique opportunity for medical oncologists, translational researchers, and drug developers from academia and industry to learn from and interact with international leaders in novel therapeutic and drug discovery platforms and to obtain a preview of agents in development for the next generation of cancer therapy.
Who Should Attend: Medical oncologists, translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. Other health care professionals interested in the treatment of cancer are also invited to attend.
Conference Agenda: Please see our website @ www.cancerlearning.com for the 3 day Agenda
Conference Fees: Please see our website for current pricing
Continuing Education: Yes